P riovant, a biotechnology company formed through a partnership between Pfizer and Roivant Sciences , has announced a "watershed moment" in the treatment of cutaneous sarcoidosis (CS) . Results from the Phase 2 Beacon trial show that brepocitinib , a dual TYK2/JAK1 inhibitor, significantly improved skin lesions in patients with this rare and often disfiguring inflammatory disease. Currently, there are no FDA-approved therapies  for cutaneous sarcoidosis, a condition affecting approximately 40,000 adults in the U.S.. Patients frequently rely on off-label treatments like corticosteroids, which can be toxic over time. The Beacon trial is the first industry-sponsored, placebo-controlled study  to generate a positive readout for this indication. The trial enrolled 31 patients, testing daily oral doses of 45 mg and 15 mg against a placebo. The 45-mg arm achieved a 100% response rate  across multiple endpoints, with all patients seeing at least a 10-point improvement on the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI). Furthermore, 62% of patients  on the higher dose reached functional remission, compared to none in the placebo group. According to Priovant CEO Ben Zimmer, the drug was well-tolerated , with no serious adverse events reported. Analysts at Leerink Partners described the findings as "exceptional,"  noting they substantially exceeded market expectations. Following these results, Roivant expects to initiate a Phase 3 study in 2026  after consulting with the FDA. This adds to a growing momentum for brepocitinib, which is already under regulatory review for dermatomyositis  and undergoing Phase 3 testing for non-infectious uveitis . Financially, Roivant remains in a strong position to fund these late-stage trials, reporting a cash balance of 4.5billion. Sales for brepocitinib are forecast to potentially reach 2.3 billion by 2032 . 🔖 Sources Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study Roivant Sciences Q3 Earnings Call Highlights Keywords: Brepocitinib for Cutaneous Sarcoidosis Brepocitinib for Cutaneous Sarcoidosis

I n a landmark achievement that could revolutionize regenerative medicine, researchers from Canada and China have developed a "universal" kidney  capable of matching any patient, regardless of their blood type,. After more than a decade of research, the team successfully utilized specialized enzymes  to convert a donor kidney from blood type A to the universal donor type O,. The breakthrough addresses a critical shortage in the organ transplant system. Currently, type O patients make up over 50% of waitlists  and often wait two to four years longer than others because type O kidneys are in high demand across all blood groups,. While ABO-incompatible transplants are currently possible, the existing process is often expensive, risky, and time-consuming , requiring intense preparation of the recipient’s immune system,. This new technique, however, focuses on modifying the organ itself. Scientists describe the enzymes as "molecular scissors"  that strip away the sugar molecules, or antigens, that act as markers for type A blood,. By removing these markers, the immune system no longer recognizes the organ as foreign—a process Dr. Stephen Withers compares to "removing the red paint from a car and uncovering the neutral primer" ,. The team tested this "enzyme-converted O" (ECO) kidney in a human model  for the first time by transplanting it into a brain-dead recipient with family consent,. The organ functioned well for several days without immediate "hyperacute" rejection,. Although the kidney began to show signs of its original type A antigens and a mild immune response by the third day, researchers noted the reaction was less severe than expected ,. While the technology is still in its early stages, it offers a path toward dramatically reducing wait times  and increasing the pool of available organs from deceased donors,. Future steps involve clinical trials and regulatory approvals to determine if standard immunosuppression can manage the long-term reappearance of antigens,. For the 11 people who die each day  in the U.S. alone while waiting for a kidney, this advancement represents a significant edge closer to real-world impact,. 🔖 Sources Scientists Created a 'Universal' Kidney To Match Any Blood Type Scientists convert a kidney from blood type A to universal type O and implant it in a brain-dead recipient Scientists Create One Kidney That Can Match Any Patient, No Matter The Blood Type Keywords: Universal Kidney Transplant Universal Kidney Transplant

A breakthrough in cardiovascular medicine was announced this week as researchers revealed that an experimental daily pill called enlicitide slashed "bad" cholesterol levels by up to 60% . The findings, published in the New England Journal of Medicine , could offer a life-changing alternative for millions of patients who struggle to reach their health goals using current treatments. The phase three clinical trial, led by Dr. Ann Marie Navar of UT Southwestern Medical Center, involved over 2,900 patients at high risk for heart disease. While statins have long been the gold standard for lowering low-density lipoprotein (LDL) cholesterol, many patients cannot reach recommended levels even with high doses. "These reductions in LDL cholesterol are the most we have ever achieved with an oral drug by far since the development of statins,"  stated Dr. Navar. The trial showed that enlicitide not only lowered LDL but also significantly reduced other harmful blood lipids over a year-long period. Enlicitide works by blocking a liver protein called PCSK9 , which normally prevents the body from clearing cholesterol from the bloodstream. While effective injectable drugs that target PCSK9 already exist, they are often underutilized because patients dislike needles and the treatment is complex to prescribe. This new oral medication offers the same level of efficacy—roughly a 60% reduction—in a much simpler pill format . Despite the excitement, researchers noted a few conditions for the drug's success. Enlicitide must be taken on an empty stomach  to remain effective. Additionally, while the pill dramatically lowers cholesterol, a larger study of 14,000 patients is currently underway to prove that this reduction directly leads to fewer heart attacks and strokes . The drugmaker Merck, which sponsored the study, is now moving toward FDA approval. The FDA has already placed enlicitide in a program for ultra-fast review , potentially bringing this new option to the public sooner than expected. For the millions of Americans living with atherosclerotic cardiovascular disease, this "experimental pill" represents the potential to prevent life-threatening cardiac events on a population level . 🔖 Sources Experimental pill dramatically reduces 'bad' cholesterol New Experimental Pill Reduces “Bad” Cholesterol by Up to 60% Experimental cholesterol-lowering pill may offer new option for millions Keywords: "Bad" Cholesterol "Bad" Cholesterol

Welcome to our Surgical Assistant preparation and certification program. The program offers a self-paced duration. If you meet all the requirements, you can apply through this pathway and complete the payment. The booking section allows you to schedule a call where we’ll provide essential information for your certification process. To ensure eligibility, please visit our services page. Feel free to ask if you need further assistance! 😊

Welcome to our Medical Assistant preparation and certification program. The program offers a self-paced duration. If you meet all the requirements, you can apply through this pathway and complete the payment. The booking section allows you to schedule a call where we’ll provide essential information for your certification process. To ensure eligibility, please visit our services page. Feel free to ask if you need further assistance! 😊

Join our 1-hour BLS course to learn how to recognize life-threatening emergencies, perform high-quality chest compressions, deliver ventilations, and use an AED effectively. Taught according to the latest American Heart Association guidelines. 🩺🌟 For more details, you can visit the Service Page. If you have any other questions, feel free to ask! 😊 What does this course teach? High-quality CPR for adults, children, and infants The AHA Chain of Survival, specifically the BLS components Important early use of an AED Effective ventilations using a barrier device Importance of teams in multirescuer resuscitation and performance as an effective team member during multirescuer CPR Relief of foreign-body airway obstruction (choking) for adults and infants

The Secret Door Testing Return

The Secret Door The "Left-Handed" Hurdle One of the most curious secrets about Thomas Brodie-Sangster’s performance in The Artful Dodger is that he had to unlearn a decade of muscle memory to play the role. While Jack Dawkins is a master surgeon in the series, Thomas actually didn't know how to use a knife and fork properly when he started—at least, not the way a high-society gentleman would. The real secret lies in his dominant hand. Thomas is left-handed, but the historical Jack Dawkins (and surgeons of the 1850s) would have been strictly trained to operate and eat with their right hand to maintain social "propriety." The Surgery Scenes: Thomas spent weeks training with a medical historian to handle scalpels and bone saws with his right hand so his movements looked authentic to the era. The Dexterity Paradox: Because he's naturally left-handed, his "clumsier" right hand actually helped convey the intense concentration and tension required for the gory, high-stakes surgeries of the 19th century. Return

Explore the best of Sherringford! Explore trending news, must-see videos, insightful tips, and more. Your ultimate guide to what's hot right now. Explore Sherringford! Explore Alex Pretti, Registered Nurse – Biography New Direct-to-Employer GLP-1 Model Aims to Lower Costs Boston Scientific Acquires Penumbra to Expand its Vascular Health Portfolio Medical Groups Sue to Restore Evidence-Based Childhood Vaccine Schedule Alex Pretti, Registered Nurse – Biography New Direct-to-Employer GLP-1 Model Aims to Lower Costs Boston Scientific Acquires Penumbra to Expand its Vascular Health Portfolio Medical Groups Sue to Restore Evidence-Based Childhood Vaccine Schedule Alex Pretti, Registered Nurse – Biography New Direct-to-Employer GLP-1 Model Aims to Lower Costs Boston Scientific Acquires Penumbra to Expand its Vascular Health Portfolio Medical Groups Sue to Restore Evidence-Based Childhood Vaccine Schedule Alex Pretti, Registered Nurse – Biography New Direct-to-Employer GLP-1 Model Aims to Lower Costs Boston Scientific Acquires Penumbra to Expand its Vascular Health Portfolio Medical Groups Sue to Restore Evidence-Based Childhood Vaccine Schedule Alex Pretti, Registered Nurse – Biography New Direct-to-Employer GLP-1 Model Aims to Lower Costs Boston Scientific Acquires Penumbra to Expand its Vascular Health Portfolio Medical Groups Sue to Restore Evidence-Based Childhood Vaccine Schedule Alex Pretti, Registered Nurse – Biography New Direct-to-Employer GLP-1 Model Aims to Lower Costs Boston Scientific Acquires Penumbra to Expand its Vascular Health Portfolio Medical Groups Sue to Restore Evidence-Based Childhood Vaccine Schedule Alex Pretti, Registered Nurse – Biography New Direct-to-Employer GLP-1 Model Aims to Lower Costs Boston Scientific Acquires Penumbra to Expand its Vascular Health Portfolio Medical Groups Sue to Restore Evidence-Based Childhood Vaccine Schedule Alex Pretti, Registered Nurse – Biography New Direct-to-Employer GLP-1 Model Aims to Lower Costs Boston Scientific Acquires Penumbra to Expand its Vascular Health Portfolio Medical Groups Sue to Restore Evidence-Based Childhood Vaccine Schedule Get Hired Fast: A Step-by-Step Job Hunt Guide Free Course Deadly Drug-Resistant Superbug Fungus Spreads Across US Healthcare Facilities News Published: January 25, 2026 U.S. Certified Healthcare Career Guide:Pathways for High School Graduates Study Last Updated: September 21, 2025 Blackcard Black Glossy Mug from $9.91 Buy Advertise with us Boost Your Brainpower: The Science of Active Recall/Retrieval Practice Study Last Updated: June 16, 2025 Hypertension Topic to review for today Review U.S. Certified Healthcare Career Guide:Pathways for High School Graduates Study Last Updated: September 21, 2025 The Clinical Case Files of House, M.D.: A List of Medical Diagnoses in House MD as a Resource for Medical Education Entertainment Last Updated: November 6, 2025 The 5 Best Scrubs for Nurses on Amazon Nursing Last Updated: June 20, 2025 Alex Pretti, Registered Nurse – Biography Read Alex Pretti, Enfermero Titulado – Biografía Read Diagnósticos Médicos en Chicago Med: Una Revisión Exhaustiva de las Condiciones Médicas en la Temporada 4 Read Medical Diagnoses in Chicago Med: A Comprehensive Review of Medical Conditions in Season 4 Read Diagnósticos Médicos en Chicago Med: Una Revisión Completa de las Condiciones Médicas de la Temporada 3 Read The Artful Dodger (2023 TV Series Review) Read St. Elsewhere (Review) Read The Artful Dodger (Reseña) Read St. Elsewhere (Reseña) Read Scrubs (Reseña) Read Bodies 2004 (Reseña) Read Scrubs TV Series (Review) Read Bodies 2004 TV series (Review) Read The Knick (Review) Read This Is Going to Hurt (Review) Read The Knick (Reseña) Read This Is Going to Hurt (Crítica) Read The Pitt (Reseña) Read House MD (Crítica) Read The Pitt (Review) Read Promote your services or products directly to our readers by purchasing available advertising space on our website. Info Advertise with us Sherringford We designed Sherringford.org to be more than just an educational resource; it's a platform intended to bring a refreshing twist to your daily professional life. Explore Main Pages Home About us Search Pricing Store Points Knowledge Library Blog News Courses Services Community Infotainment MH Colaboration Advertise with us Suggestions Work with us Publish on our blog Publish mentor availability Find a mentor Donations Comply Private Policy Disclosure Terms and Conditions Do Not Sell My Personal Information